JP7032425B2 - Ｍｕｃ１に特異的に結合する抗体及びその用途 - Google Patents

Ｍｕｃ１に特異的に結合する抗体及びその用途 Download PDF

Info

Publication number
JP7032425B2
JP7032425B2 JP2019552556A JP2019552556A JP7032425B2 JP 7032425 B2 JP7032425 B2 JP 7032425B2 JP 2019552556 A JP2019552556 A JP 2019552556A JP 2019552556 A JP2019552556 A JP 2019552556A JP 7032425 B2 JP7032425 B2 JP 7032425B2
Authority
JP
Japan
Prior art keywords
antibody
muc1
cancer
cells
hmuc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515249A (ja
JP2020515249A5 (https=
Inventor
キョンドク ムン
ホイル チェ
Original Assignee
ペプトロン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペプトロン インコーポレイテッド filed Critical ペプトロン インコーポレイテッド
Priority claimed from PCT/KR2018/003267 external-priority patent/WO2018174544A2/ko
Publication of JP2020515249A publication Critical patent/JP2020515249A/ja
Publication of JP2020515249A5 publication Critical patent/JP2020515249A5/ja
Priority to JP2021158853A priority Critical patent/JP7158548B2/ja
Priority to JP2021158852A priority patent/JP7158547B2/ja
Application granted granted Critical
Publication of JP7032425B2 publication Critical patent/JP7032425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
JP2019552556A 2017-03-21 2018-03-21 Ｍｕｃ１に特異的に結合する抗体及びその用途 Active JP7032425B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021158853A JP7158548B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途
JP2021158852A JP7158547B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20170035622 2017-03-21
KR10-2017-0035622 2017-03-21
KR1020180032592A KR102127421B1 (ko) 2017-03-21 2018-03-21 Muc1에 특이적으로 결합하는 항체 및 그의 용도
KR10-2018-0032592 2018-03-21
PCT/KR2018/003267 WO2018174544A2 (ko) 2017-03-21 2018-03-21 Muc1에 특이적으로 결합하는 항체 및 그의 용도

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021158853A Division JP7158548B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途
JP2021158852A Division JP7158547B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途

Publications (3)

Publication Number Publication Date
JP2020515249A JP2020515249A (ja) 2020-05-28
JP2020515249A5 JP2020515249A5 (https=) 2020-07-30
JP7032425B2 true JP7032425B2 (ja) 2022-03-08

Family

ID=63877998

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552556A Active JP7032425B2 (ja) 2017-03-21 2018-03-21 Ｍｕｃ１に特異的に結合する抗体及びその用途
JP2021158852A Active JP7158547B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途
JP2021158853A Active JP7158548B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021158852A Active JP7158547B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途
JP2021158853A Active JP7158548B2 (ja) 2017-03-21 2021-09-29 Ｍｕｃ１に特異的に結合する抗体及びその用途

Country Status (12)

Country Link
US (4) US11472887B2 (https=)
EP (2) EP3825328A1 (https=)
JP (3) JP7032425B2 (https=)
KR (2) KR102127421B1 (https=)
CN (1) CN111201240B (https=)
AU (3) AU2018238165C1 (https=)
BR (1) BR112019019650A2 (https=)
CA (1) CA3056582C (https=)
IL (1) IL269488B2 (https=)
MX (1) MX2019011101A (https=)
RU (1) RU2746413C1 (https=)
ZA (1) ZA201906813B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269488B2 (en) 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use
AU2020290579B2 (en) 2019-06-14 2026-02-12 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1 and methods of use thereof
MX2022011553A (es) * 2020-03-18 2023-01-04 Biomodifying Llc Anticuerpos anti-sea de muc1.
KR102811084B1 (ko) * 2020-12-24 2025-05-23 주식회사 엘지화학 뮤신 1에 특이적인 폴리펩티드 및 이의 이용
WO2023009759A2 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
CN114028539B (zh) * 2021-09-13 2024-04-26 北京大学 粘蛋白1在抑制冠状病毒中的应用
CN114106110B (zh) * 2021-11-25 2025-04-18 国家纳米科学中心 一种特异性结合muc1蛋白的多肽、靶向载药共递送系统及其制备方法与应用
AU2022434346A1 (en) * 2022-01-24 2024-07-25 Cyron Therapeutics Co., Ltd. Antibody specifically binding to muc-1 and uses thereof
CN116554317B (zh) * 2022-01-29 2025-02-28 浙江纳米抗体技术中心有限公司 Muc1结合分子及其应用
KR20250009592A (ko) * 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
CN120513260A (zh) * 2023-01-09 2025-08-19 百奥赛图(北京)医药科技股份有限公司 抗egfr/muc1抗体及其应用
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
EP4676976A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 antibodies and methods of use
CN120882753A (zh) * 2023-04-13 2025-10-31 江苏恒瑞医药股份有限公司 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途
WO2025026358A1 (zh) * 2023-08-01 2025-02-06 浙江纳米抗体技术中心有限公司 Muc1结合分子和包含其的嵌合抗原受体
WO2025080693A1 (en) * 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof
WO2025218621A1 (zh) * 2024-04-15 2025-10-23 原启生物科技(上海)有限责任公司 靶向muc1的抗原结合蛋白
CN121287878A (zh) * 2024-07-08 2026-01-09 元本(珠海横琴)生物科技有限公司 CpG1018/1826/007/2006联合MNR的组合物用于治疗胰腺癌

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515472A (ja) 2000-09-11 2004-05-27 ドナルド ダブリュー． クフェ， Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
JP2005508839A (ja) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US20070105767A1 (en) 2003-10-24 2007-05-10 Surender Kharbanda Modulation of the interaction of muc1 with muc1 ligands
JP2017505625A (ja) 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101346197B1 (ko) * 2009-07-17 2014-02-06 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515472A (ja) 2000-09-11 2004-05-27 ドナルド ダブリュー． クフェ， Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
JP2005508839A (ja) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US20070105767A1 (en) 2003-10-24 2007-05-10 Surender Kharbanda Modulation of the interaction of muc1 with muc1 ligands
JP2017505625A (ja) 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun.，2011年02月18日，Vol.405, No.3，pp.377-381

Also Published As

Publication number Publication date
EP3604334A4 (en) 2021-03-31
US20230092610A1 (en) 2023-03-23
US20200024361A1 (en) 2020-01-23
RU2746413C1 (ru) 2021-04-13
ZA201906813B (en) 2020-08-26
JP2020515249A (ja) 2020-05-28
EP3604334A2 (en) 2020-02-05
AU2020281130A1 (en) 2021-01-07
CN111201240A (zh) 2020-05-26
US11739159B2 (en) 2023-08-29
KR20200079226A (ko) 2020-07-02
JP7158548B2 (ja) 2022-10-21
AU2020281132B2 (en) 2023-06-08
AU2020281130B2 (en) 2023-05-25
AU2020281132A1 (en) 2021-01-07
US20210115153A1 (en) 2021-04-22
US20230055818A1 (en) 2023-02-23
BR112019019650A2 (pt) 2020-06-30
CA3056582A1 (en) 2018-09-27
JP2022023078A (ja) 2022-02-07
AU2018238165A8 (en) 2019-11-07
AU2018238165B2 (en) 2020-11-26
KR102169224B1 (ko) 2020-10-23
JP2022008618A (ja) 2022-01-13
US11472887B2 (en) 2022-10-18
US11718684B2 (en) 2023-08-08
KR20180107005A (ko) 2018-10-01
AU2018238165C1 (en) 2021-03-18
US11739158B2 (en) 2023-08-29
EP3825328A1 (en) 2021-05-26
IL269488A (https=) 2019-11-28
AU2018238165A1 (en) 2019-10-24
CN111201240B (zh) 2024-03-22
CA3056582C (en) 2022-05-31
IL269488B1 (en) 2023-05-01
KR102127421B1 (ko) 2020-06-26
JP7158547B2 (ja) 2022-10-21
MX2019011101A (es) 2020-07-14
IL269488B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7032425B2 (ja) Ｍｕｃ１に特異的に結合する抗体及びその用途
US20080286198A1 (en) Novel anti-IGF-IR antibodies and uses thereof
ITTO20080313A1 (it) Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
JP2026053502A (ja) Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
US20190160180A1 (en) Endosialin-binding antibody
US20080063639A1 (en) Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
KR20230078152A (ko) Psma에 특이적으로 결합하는 항체 및 그의 용도
TWI855692B (zh) 抗cd200r1抗體
KR20260016896A (ko) 항-베타2-마이크로글로불린 항체 및 이의 용도
KR20250160321A (ko) 항-메소텔린 항체 및 이의 용도
WO2026082125A1 (zh) 结合folr1的抗体、含有其的药物及其应用
WO2025133322A1 (en) Cnx antigen-binding molecules

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220224

R150 Certificate of patent or registration of utility model

Ref document number: 7032425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250